An observational study in Obesity, sponsored by Blekinge County Council Hospital. Status unknown at 1 site in Sweden. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-04-30.
Sponsored by Blekinge County Council Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Obesity with a site in Sweden — 38 open to participants now, 49 under way, 8 of them phase 3. Obesity · Sweden.
Among the 179 studies in Obesity with a site in Sweden, this one is the 16th largest by enrollment of the 30 observational ones that give a count, is one of 13 that started in 2014, is one of 30 observational ones, and was the 79th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →38 of the 179 studies in Obesity with a site in Sweden are open now. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18–64 · Women only
AstraZeneca · Sites in Sweden, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Sweden, United States, Belgium and 7 more countries
Ages 18+
Novo Nordisk A/S · Sites in Sweden, United States, Greece and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in Sweden, Germany
Ages 18–70 · Healthy volunteers
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 18 · Phase 3 27 · Phase 4 7
First in 1987; this study’s year is marked. 13 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 110 across the 149 interventional studies, 103 across the 30 observational. Of the 109 that completed or were terminated, 12 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 179 have an industry lead sponsor. The 10 most frequent:
Blekinge County Council Hospital is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Blekinge County Council Hospital has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07213245Göteborg UniversityMetabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) | 2026-12-31 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07665879Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 179 studies in Obesity with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare Gastric Bypass and AspireAssist Aspiration Therapy over 5 years of treatment with regards to weight loss, quality of life, complications, adverse events, and health economics.
Overweight and obesity is increasing rapidly in Sweden and is the greatest threat to future public health. Obesity, defined according to the World Health Organization (WHO) as a body mass index (BMI) greater than 30 kg/m2, is an intractable disease in healthcare today. Obesity results in reduced life expectancy and increased morbidity.
Weight reduction by lifestyle changes or with different pharmacological preparations have in many studies not made lasting long term results. Obesity surgery has so far been the only way to achieve permanent weight loss. During the 1980s, restrictive procedures were performed, e.g., vertical banded gastro-plasty (VBG) with good but unfortunately transient effect. Later developed, is the now prevalent gastric bypass procedure (GBP) which today uses the keyhole technique and causes combined restrictive and mal-absorptive changes in gastrointestinal anatomy.
GBP is currently the standard method in clinical practice for the surgical treatment of morbid obesity (i.e., BMI over 35). GBP is a procedure that is not reversible, which entail certain pre - and postoperative risks. GBP quickly brings a sharp reduction in weight and also regression of diabetes mellitus type 2. Unfortunately, the surgery cause lifelong mal-absorption and requirements of vitamin and mineral supplements.
Swedish Obese Subjects study (SOS) that emanated from Gothenburg was the first controlled intervention study of overweight individuals. Approximately 4000 patients were included, half of which were surgical, the other half were treated optimally, but without surgery. The patients have been followed for 10-20 years. Total mortality was 24% lower in the surgical group.
A new alternative approach to obesity surgery, AspireAssist™ Aspiration Therapy System (CE Marked), comes from the United States and in this method the individual empties out digesta from the stomach. Percutaneous endoscopic gastrostomy (PEG) has been used internationally since the early 1980s for nutrition therapy for stroke or cancer. In a gastroscopy a tube is placed between the stomach and abdominal wall and nutrition administered via tube directly into the stomach.
Aspiration treatment with AspireAssist™ empties food from the stomach after every meal to lose weight. Using a valve mechanism and associated tubing set and water reservoir the individual empties out digesta in the toilet 20 minutes after each meal and loses approximately 30% of the caloric intake in the diet. A 1 -year study in Karlskrona, Sweden, has shown a significant reduction in weight, almost 40% Excess Weight Loss (% EWL) reduction and median weight reduction of 16.5 kg after 6 months. For GBP the weight reduction of 1 year is in the order of 70-85 %. During 1 year of treatment with AspireAssist™ there were no serious complications or problems with the body's electrolyte balance noted either at the surgery or during follow-up. The advantage of this method is that it is completely reversible and the individual who does not wish to continue aspiration may have the tube into the stomach removed. GBP results in most of the stomach becoming disconnected and not accessible for the diagnosis of, for example, ulcers, bleeding, tumors or gall stones. AspireAssist™ does not have any lasting changes in the anatomy and thus will not lead to the potential for internal hernia that GBP unfortunately can cause. Wound infection occurs in approximately 9 % of cases when PEG tubes are placed in patients with cancer or stroke. Wound infections are, in most cases, treatable with antibiotics in tablet form and are very rarely considered to be a serious complication. Antibiotics are routinely given in conjunction with PEG insertion. Very unusual complication is leakage associated with insertion of the PEG and the method has been reported to have a risk of about 2 % during PEG insertion.
For the individual to get help to change their habits and their lifestyle, cognitive behavioral therapy (CBT) is included in the treatment concept for AspireAssist™. CBT program runs for six months and includes both group meetings and individual conversations and individual assignments between meetings. Group meetings will cover the following themes: motivation, vision workshop, self-esteem, thought management, stress, learn to eat consciously, prevent and manage relapse. The program uses no calorie reducing methods since there is no scientific evidence that these provide permanent results but are based on CBT. The program is enhanced with awareness and mental training, which are methods that have shown good results in stress-related conditions. Mindfulness Based Stress Reduction (MBSR) in one study has been shown to change brain activity of the participants so that the activity was shifted from the areas in the frontal lobe that is active during stress, anxiety and depression to areas that regulate peace, joy and curiosity.
Randomization in clinical trial (RCT) had been the best way to implement such a comparative study. But AspireAssist™ method is aimed at patients who do not want or dare to be operated with Gastric Bypass Procedure (GBP) and therefore fails to randomization.
We therefore recruit patients from the clinic's waiting list of accepted and planned the GBP and the other group comes from the existing waiting list for Aspire method to treat obesity. This group includes only those patients who expressed clearly that they are not willing or dare to be operated with GBP, but instead wishes to receive treatment with Aspire method for their morbid obesity.
There are now newer statistical methods to compare two or more groups in an observational study in a good and statistically significant manner and Stata version 13 can handle it well by matching the so-called covariates (e.g., in our study may be covariates following variables at baseline: age, gender, preoperative weight, BMI, concomitant disease such as diabetes). Patients were matched and then the comparison is done between the matched groups. Calculation of treatment effects , including so-called propensity score exploitation has already been used in a comparative study between GBP and other bariatric surgery for obesity where neither has been able to randomize patients (Carlin et al Annals of Surgery, Vol. 257, Number 5, May 2013: 791-7)
The study is a prospective investigation of patients in Blekinge with a diagnosis of obesity. A total of 100 patients will be included consecutively in the study. The distribution will be 50 patients for each group. Recruitment for Gastric Bypass is made from the clinic's waiting list for obesity surgery and for AspireAssist those individuals' self-reported interest for treatment with AspireAssist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
Procedure: Gastric Bypass
Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
Device: AspireAssist Aspiration Therapy
Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
Weight Loss
% Excess Weight loss based on ideal body weight with BMI of 25
Time frame: year 1 - quarterly, years 2-5 once per year
Quality of Life
Quality of Life survey according to EQ-5D EuroQol survey
Time frame: annually, up to 5 years
Complications
any surgical or post surgical complications, therapy related illness or adverse events
Time frame: within 30 days of procedure, after 30 days
Plan to share: No — There is no plan to share individual participant data.
No publications or documents are linked to this record.
Started May 2014 (actual). Primary completion is estimated for May 2020, 72 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 72 months is above that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blekinge County Council Hospital